Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children
-
Sercin Guven
,
Ibrahim Gokce
Abstract
Background
Sclerostin and osteoprotegerin (OPG) are new markers of chronic kidney disease (CKD) mediated mineral bone disease (CKD-MBD) which were extensively evaluated in adult population. We aimed to evaluate the associations between serum levels of sclerostin/OPG and parameters of bone turnover and compare the serum levels of sclerostin/OPG in different stages of CKD in children.
Methods
70 children with CKD stage 1-5, aged 2-21 years were examined. Serum levels of alkaline phosphatase (ALP), creatinine, total calcium, phosphorus , intact parathyroid hormone (iPTH) and vitamin D were measured. Serum sclerostin and OPG levels were measured in children with different levels of CKD stage and their association with bone turnover parameters were noted.
Results
We did not observe any significant correlation between serum levels of sclerostin and OPG and stages of CKD. A negative relationship was present between serum sclerostin and 25-OH vitamin D levels. Osteoprotegerin was positively and significantly correlated with ALP but serum sclerostin was negatively correlated with ALP.
Conclusion
Our study, which includes only children and adolescents with a growing skeleton under uremic conditions and excluding diabetes and atherosclerosis interference, is very valuable. We couldn't find any significant relationship between either sclerostin or OPG levels among different stages of CKD. Also our study demonstared a strong negative relationship between ALP and sclerostin levels and a strong positive relationship between ALP and OPG levels, reminding the importance of ALP levels to predict the bone-mineral status of the children with CKD.
Research funding: The authors have no financial relationships relevant to this article to disclose.
Author contributions: Sercin Guven: Dr. Guven conceptualized and designed the study, coordinated and supervised data collection, drafted the initial manuscript and approved the final manuscript as submitted.
Ibrahim Gokce: Dr. Gokce coordinated and supervised data collection, drafted the initial manuscript, reviewed and revised the manuscript, and approved the final manuscript as submitted.
Neslihan Cicek: Dr. Cicek coordinated and supervised data collection.
Ali Yaman and Pinar Vatansever: Drs Yaman and Vatansever coordinated biochemical analyses.
Harika Alpay: Dr Alpay carried out the initial analyses, critically reviewed and revised the manuscript, and approved the final manuscript as submitted.
Conflicts of Interest: The authors have no conflicts of interest relevant to this article to disclose.
Informed consent: Informed consent was obtained from all individuals included in this study.
References
1. Bowden, SA, Akusoba, CI, Hayes, JR, Mahan, JD. Biochemical markers of bone turnover in children with clinical bone fragility. J Pediatr Endocrinol Metab 2016;29:715-22. https://doi.org/10.1515/jpem-2014-0525.Search in Google Scholar
2. Lu, KC, Wu, CC, Yen, JF, Liu, WC. Vascular calcification and renal bone disorders. ScientificWorldJournal 2014;2014:637065. https://doi.org/10.1155/2014/637065.Search in Google Scholar
3. Pereira, L, Frazco, JM. The bone-vessel axis in chronic kidney disease: an update on biochemical players and its future role in laboratory medicine. Clin Chim Acta 2020;508:221-7. https://doi.org/10.1016/j.cca.2020.05.023.Search in Google Scholar
4. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39:1-266.Search in Google Scholar
5. Schwartz, GJ, Brion, LP, Spitzer, A. The use of plasma creatinin concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin 1987;34:571-90. https://doi.org/10.1016/s0031-3955(16)36251-4.Search in Google Scholar
6. Mvdder, UI, Hoey, KA, Amin, S, McCready, LK, Achenbach, SJ, Riggs, L, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011;26:373-9. https://doi.org/10.1002/jbmr.217.Search in Google Scholar PubMed PubMed Central
7. Morena, M, Jaussen, I, Dupu, AM, Bargnoux, AS, Kuster, N, Chenine, L, et al. Osteoprotegerin and sclersotin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dil Transplant 2015;30:1345-56. https://doi.org/10.1093/ndt/gfv081.Search in Google Scholar PubMed
8. Cejka, D, Herberth, J, Branscum, AJ, Fardo, DW, Monier-Faugere, MC, Diarra, D, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011;6:877-82. https://doi.org/10.2215/cjn.06550810.Search in Google Scholar PubMed PubMed Central
9. Pelletier, S, Dubourg, L, Carlier, MC, Hadj-Aissa, A, Fouque, D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013;8:819-23. https://doi.org/10.2215/cjn.07670712.Search in Google Scholar
10. Kanbay, M, Siriopol, D, Saglam, M, Kurt, YC, Gok, M, Cetinkaya, H, et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. Clin Endocrinol Metabol 2014;99:E1854-61. https://doi.org/10.1210/jc.2014-2042.Search in Google Scholar PubMed
11. Jiang, JQ, Lin, S, Xu, PC, Zheng, ZF, Jia, JY. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease- mineral and bone disorder. Nephrology 2011;16:588-94. https://doi.org/10.1111/j.1440-1797.2011.01481.x.Search in Google Scholar PubMed
12. Sigrist, MK, Levin, A, Er, L, McIntyre, CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009;24:3157-62. https://doi.org/10.1093/ndt/gfp253.Search in Google Scholar PubMed
13. Sato, T, Tominaga, Y, Iwasaki, Y, Kazama, JJ, Shigematsu, T, Inagaki, H, et al. Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 2001;38:175-7. 4 Suppl 1. https://doi.org/10.1053/ajkd.2001.27437.Search in Google Scholar PubMed
14. Swolin-Eide, D, Hansson, S, Magnusson, P. Children with chronic kidney disease: a 3-year prospective study of growth, bone mass and bone turnover. Acta Paediatr 2009;98:367-73. https://doi.org/10.1111/j.1651-2227.2008.01073.x.Search in Google Scholar PubMed
15. Zislkowska, H, Roszkowska-Blaim, M. Osteoprotegerin and calcium-phosphorus metabolism parameters in children with chronic renal failure. Przegl Lek 2006;63:68-71. Suppl 3.Search in Google Scholar
16. Dr|eke, TB, Lafage-Proust, MH. Sclerostin: just one more player in renal bone disease?. Clin J Am Soc Nephrol 2011;6:700-3. https://doi.org/10.2215/cjn.01370211.Search in Google Scholar PubMed
17. Ardawi, M-SM, Al-Kadi, HA, Rouzi, AA, Qari, MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011;26:2812-22. https://doi.org/10.1002/jbmr.479.Search in Google Scholar PubMed
18. Garcma-Martmn, A, Rozas-Moreno, P, Reyes-Garcma, R, Morales-Santana, S, Garcma-Fontana, B, Garcma-Salcedo, J, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metabol 2012;97:234-41. https://doi.org/10.1210/jc.2011-2186.Search in Google Scholar PubMed
19. Ryan, ZC, Ketha, H, McNulty, MS, McGee-Lawrence, M, Craig, TA, Grande, JP, et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A 2013;110:6199-204. https://doi.org/10.1073/pnas.1221255110.Search in Google Scholar PubMed PubMed Central
20. Montaqez-Barragan, A, Gsmez-Barrera, I, Sanchez-Niqo, MD, Ucero, AC, Gonzalez-Espinoza, L, Ortiz, A. Osteoprotegerin and kidney disease. J Nephrol 2014;27:607-17. https://doi.org/10.1007/s40620-014-0092-x.Search in Google Scholar PubMed
21. Figurek, A, Rroji, M, Spasovski, G. Sclerostin: a new biomarker of CKD-MBD. Int Urol Nephrol 2020;52:107-13. https://doi.org/10.1007/s11255-019-02290-3.Search in Google Scholar PubMed
22. Kramer, I, Loots, GG, Studer, A, Keller, H, Kneissel, M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010;25:178-89. https://doi.org/10.1359/jbmr.090730.Search in Google Scholar PubMed PubMed Central
23. Siomou, E, Challa, A, Printza, N, Giapros, V, Petropoulou, F, Mitsioni, A, Papachristou, F, Stefanidis, CJ. Serum ostoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol 2011;26:1105-14. https://doi.org/10.1007/s00467-011-1870-5.Search in Google Scholar PubMed
24. Goldsmith, D, Covic, A, Vervloet, M, Cozzolino, M, Nistor, I. Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board; Chronic Kidney Disease-Mineral Bone Disease CKD-MBD working group and the European Renal Best Practice ERBP advisory board. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant 2015;30:698-700. https://doi.org/10.1093/ndt/gfv050.Search in Google Scholar PubMed
25. Bakkaloglu, SA, Wesseling-Perry, K, Pereira, RC, Gales, B, Wang, HJ, Elashoff, RM, et al. Value of the new bone classification system in pediatric renal osteodistrophy. Clin J Am Soc Nephrol 2010;5:1860-6. https://doi.org/10.2215/cjn.01330210.Search in Google Scholar
Supplementary material
The online version of this article offers supplementary material (https://doi.org/10.1515/jpem-2020-0140).
(c) 2020 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review Article
- The influence of growth hormone therapy on the cardiovascular system in Turner syndrome
- Original Articles
- Clinical utility of urinary gonadotrophins in hypergonadotrophic states as Turner syndrome
- Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children
- Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment
- Mechanisms and early patterns of dyslipidemia in pediatric type 1 and type 2 diabetes
- Frequency of thyroid dysfunction in pediatric patients with congenital heart disease exposed to iodinated contrast media – a long-term observational study
- Effect of growth hormone therapy on thyroid function in isolated growth hormone deficient and short small for gestational age children: a two-year study, including on assessment of the usefulness of the thyrotropin-releasing hormone (TRH) stimulation test
- Clinical relevance of T lymphocyte subsets in pediatric Graves’ disease
- Long-term follow-up of differentiated thyroid carcinoma in children and adolescents
- A quality improvement project for managing hypocalcemia after pediatric total thyroidectomy
- Pubertal development and adult height in patients with congenital hypothyroidism detected by neonatal screening in southern Brazil
- Clinical characteristics, surgical approach, BRAFV600E mutation and sodium iodine symporter expression in pediatric patients with thyroid carcinoma
- BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation
- Case Reports
- Pseudohypoparathyroidism type 1B (PHP1B), a rare disorder encountered in adolescence
- Impaired glucose homeostasis and a novel HLCS pathogenic variant in holocarboxylase synthetase deficiency: a report of two cases and brief review
- Transcobalamin II deficiency in twins with a novel variant in the TCN2 gene: case report and review of literature
- Aldosterone deficiency with a hormone profile mimicking pseudohypoaldosteronism
- Non-classical lipoid adrenal hyperplasia presenting as hypoglycemic seizures
Articles in the same Issue
- Frontmatter
- Review Article
- The influence of growth hormone therapy on the cardiovascular system in Turner syndrome
- Original Articles
- Clinical utility of urinary gonadotrophins in hypergonadotrophic states as Turner syndrome
- Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children
- Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment
- Mechanisms and early patterns of dyslipidemia in pediatric type 1 and type 2 diabetes
- Frequency of thyroid dysfunction in pediatric patients with congenital heart disease exposed to iodinated contrast media – a long-term observational study
- Effect of growth hormone therapy on thyroid function in isolated growth hormone deficient and short small for gestational age children: a two-year study, including on assessment of the usefulness of the thyrotropin-releasing hormone (TRH) stimulation test
- Clinical relevance of T lymphocyte subsets in pediatric Graves’ disease
- Long-term follow-up of differentiated thyroid carcinoma in children and adolescents
- A quality improvement project for managing hypocalcemia after pediatric total thyroidectomy
- Pubertal development and adult height in patients with congenital hypothyroidism detected by neonatal screening in southern Brazil
- Clinical characteristics, surgical approach, BRAFV600E mutation and sodium iodine symporter expression in pediatric patients with thyroid carcinoma
- BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation
- Case Reports
- Pseudohypoparathyroidism type 1B (PHP1B), a rare disorder encountered in adolescence
- Impaired glucose homeostasis and a novel HLCS pathogenic variant in holocarboxylase synthetase deficiency: a report of two cases and brief review
- Transcobalamin II deficiency in twins with a novel variant in the TCN2 gene: case report and review of literature
- Aldosterone deficiency with a hormone profile mimicking pseudohypoaldosteronism
- Non-classical lipoid adrenal hyperplasia presenting as hypoglycemic seizures
